Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing radiopharmaceuticals.
Fusion Pharmaceuticals has raised $60.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2023.
Fusion Pharmaceuticals's investors include Perceptive Advisors, Adams Street Partners, OrbiMed, Rock Springs Capital, Johnson & Johnson Innovation.
Fusion Pharmaceuticals is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing radiopharmaceuticals.
Fusion Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Fusion Pharmaceuticals — Funding & Investors." VCBacked, February 13, 2023, https://www.vcbacked.co/company/fusion-pharmaceuticals. Accessed August 16, 2026.
VCBacked. (2023). Fusion Pharmaceuticals — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/fusion-pharmaceuticals
{{cite web |title=Fusion Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/fusion-pharmaceuticals |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated